Investment analysts at Evercore ISI assumed coverage on shares of Caribou Biosciences (NASDAQ:CRBU – Get Free Report) in a research note issued on Tuesday, Briefing.com reports. The firm set an “outperform” rating and a $13.00 price target on the stock. Evercore ISI’s price objective would suggest a potential upside of 263.13% from the company’s previous close.
Several other equities analysts also recently issued reports on the stock. Truist Financial started coverage on shares of Caribou Biosciences in a report on Tuesday, July 11th. They set a “buy” rating and a $23.00 price target for the company. Citigroup dropped their target price on shares of Caribou Biosciences from $37.00 to $30.00 in a report on Tuesday, September 5th. Finally, HC Wainwright decreased their target price on shares of Caribou Biosciences from $25.00 to $23.00 and set a “buy” rating for the company in a report on Wednesday, July 26th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Caribou Biosciences currently has an average rating of “Buy” and a consensus target price of $23.57.
View Our Latest Analysis on CRBU
Caribou Biosciences Trading Down 1.4 %
Caribou Biosciences (NASDAQ:CRBU – Get Free Report) last released its earnings results on Tuesday, August 8th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.01. Caribou Biosciences had a negative net margin of 780.23% and a negative return on equity of 37.93%. The business had revenue of $3.76 million for the quarter, compared to analysts’ expectations of $3.45 million. Analysts predict that Caribou Biosciences will post -1.61 EPS for the current year.
Hedge Funds Weigh In On Caribou Biosciences
Several institutional investors have recently added to or reduced their stakes in the company. NewEdge Advisors LLC grew its position in Caribou Biosciences by 187.3% during the 1st quarter. NewEdge Advisors LLC now owns 5,100 shares of the company’s stock worth $27,000 after acquiring an additional 3,325 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Caribou Biosciences by 88.1% in the second quarter. Tower Research Capital LLC TRC now owns 6,871 shares of the company’s stock valued at $29,000 after buying an additional 3,218 shares in the last quarter. Royal Bank of Canada grew its stake in shares of Caribou Biosciences by 52.3% during the second quarter. Royal Bank of Canada now owns 8,106 shares of the company’s stock valued at $34,000 after purchasing an additional 2,785 shares during the last quarter. Ameritas Investment Partners Inc. increased its holdings in shares of Caribou Biosciences by 168.4% in the first quarter. Ameritas Investment Partners Inc. now owns 3,945 shares of the company’s stock valued at $36,000 after purchasing an additional 2,475 shares in the last quarter. Finally, Ergoteles LLC bought a new position in Caribou Biosciences in the 2nd quarter worth approximately $53,000. 59.16% of the stock is owned by institutional investors.
Caribou Biosciences Company Profile
Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma.
Read More
- Five stocks we like better than Caribou Biosciences
- Best Stocks Under $10.00
- First Solar, an affordable, high-quality green investment
- 3 Grocery Stocks That Are Proving They Are Still Essential
- 5 Dow stocks to track during the market correction
- Following Congress Stock Trades
- Lean on these stocks during GDP expansion
Receive News & Ratings for Caribou Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caribou Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
